Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M. Lamarre D, et al. Among authors: kukolj g. Nature. 2003 Nov 13;426(6963):186-9. doi: 10.1038/nature02099. Epub 2003 Oct 26. Nature. 2003. PMID: 14578911 Free article. Clinical Trial.
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, Thibeault D, Kukolj G. White PW, et al. Among authors: kukolj g. Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8. doi: 10.1128/AAC.00787-10. Epub 2010 Sep 7. Antimicrob Agents Chemother. 2010. PMID: 20823284 Free PMC article.
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Lagacé L, White PW, Bousquet C, Dansereau N, Dô F, Llinas-Brunet M, Marquis M, Massariol MJ, Maurice R, Spickler C, Thibeault D, Triki I, Zhao S, Kukolj G. Lagacé L, et al. Among authors: kukolj g. Antimicrob Agents Chemother. 2012 Jan;56(1):569-72. doi: 10.1128/AAC.05166-11. Epub 2011 Oct 24. Antimicrob Agents Chemother. 2012. PMID: 22024816 Free PMC article.
Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.
Beaulieu PL, Coulombe R, Duan J, Fazal G, Godbout C, Hucke O, Jakalian A, Joly MA, Lepage O, Llinàs-Brunet M, Naud J, Poirier M, Rioux N, Thavonekham B, Kukolj G, Stammers TA. Beaulieu PL, et al. Among authors: kukolj g. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4132-40. doi: 10.1016/j.bmcl.2013.05.037. Epub 2013 May 23. Bioorg Med Chem Lett. 2013. PMID: 23768906
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.
Hucke O, Coulombe R, Bonneau P, Bertrand-Laperle M, Brochu C, Gillard J, Joly MA, Landry S, Lepage O, Llinàs-Brunet M, Pesant M, Poirier M, Poirier M, McKercher G, Marquis M, Kukolj G, Beaulieu PL, Stammers TA. Hucke O, et al. Among authors: kukolj g. J Med Chem. 2014 Mar 13;57(5):1932-43. doi: 10.1021/jm4004522. Epub 2013 Jul 12. J Med Chem. 2014. PMID: 23773186
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.
Berger KL, Lagacé L, Triki I, Cartier M, Marquis M, Lawetz C, Bethell R, Scherer J, Kukolj G. Berger KL, et al. Among authors: kukolj g. Antimicrob Agents Chemother. 2013 Oct;57(10):4928-36. doi: 10.1128/AAC.00822-13. Epub 2013 Jul 22. Antimicrob Agents Chemother. 2013. PMID: 23877706 Free PMC article. Clinical Trial.
77 results